These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27121883)

  • 1. Therapeutic vaccination strategies to treat nasopharyngeal carcinoma.
    Taylor GS; Steven NM
    Chin Clin Oncol; 2016 Apr; 5(2):23. PubMed ID: 27121883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effective treatment of metastatic forms of Epstein-Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy.
    Smith C; Tsang J; Beagley L; Chua D; Lee V; Li V; Moss DJ; Coman W; Chan KH; Nicholls J; Kwong D; Khanna R
    Cancer Res; 2012 Mar; 72(5):1116-25. PubMed ID: 22282657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapeutic approaches in EBV-associated nasopharyngeal carcinoma.
    Li W; Duan X; Chen X; Zhan M; Peng H; Meng Y; Li X; Li XY; Pang G; Dou X
    Front Immunol; 2022; 13():1079515. PubMed ID: 36713430
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapeutic approaches in nasopharyngeal carcinoma.
    Chow JC; Ngan RK; Cheung KM; Cho WC
    Expert Opin Biol Ther; 2019 Nov; 19(11):1165-1172. PubMed ID: 31361154
    [No Abstract]   [Full Text] [Related]  

  • 5. Prophylactic and therapeutic strategies for Epstein-Barr virus-associated diseases: emerging strategies for clinical development.
    Dasari V; Sinha D; Neller MA; Smith C; Khanna R
    Expert Rev Vaccines; 2019 May; 18(5):457-474. PubMed ID: 30987475
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular-based immunotherapy in Epstein-Barr virus induced nasopharyngeal cancer.
    Lee AZE; Tan LSY; Lim CM
    Oral Oncol; 2018 Sep; 84():61-70. PubMed ID: 30115477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EBV latent membrane protein 1 augments γδ T cell cytotoxicity against nasopharyngeal carcinoma by induction of butyrophilin molecules.
    Liu Y; Lui KS; Ye Z; Fung TY; Chen L; Sit PY; Leung CY; Mak NK; Wong KL; Lung HL; Tanaka Y; Cheung AKL
    Theranostics; 2023; 13(2):458-471. PubMed ID: 36632221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytotoxic T cell adoptive immunotherapy as a treatment for nasopharyngeal carcinoma.
    Lutzky VP; Crooks P; Morrison L; Stevens N; Davis JE; Corban M; Hall D; Panizza B; Coman WB; Coman S; Moss DJ
    Clin Vaccine Immunol; 2014 Feb; 21(2):256-9. PubMed ID: 24351754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human Leukocyte Antigen (HLA) A*1101-Restricted Epstein-Barr Virus-Specific T-cell Receptor Gene Transfer to Target Nasopharyngeal Carcinoma.
    Zheng Y; Parsonage G; Zhuang X; Machado LR; James CH; Salman A; Searle PF; Hui EP; Chan AT; Lee SP
    Cancer Immunol Res; 2015 Oct; 3(10):1138-47. PubMed ID: 25711537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
    Cui X; Snapper CM
    Front Immunol; 2021; 12():734471. PubMed ID: 34691042
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell therapy for EBV-associated nasopharyngeal carcinoma: preparative lymphodepleting chemotherapy does not improve clinical results.
    Secondino S; Zecca M; Licitra L; Gurrado A; Schiavetto I; Bossi P; Locati L; Schiavo R; Basso S; Baldanti F; Maccario R; Locatelli F; Siena S; Pedrazzoli P; Comoli P
    Ann Oncol; 2012 Feb; 23(2):435-41. PubMed ID: 21586688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Therapies Boosting T Cell Immunity in Epstein Barr Virus-Associated Nasopharyngeal Carcinoma.
    Renaud S; Lefebvre A; Mordon S; Moralès O; Delhem N
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus infection and nasopharyngeal carcinoma: the other side of the coin.
    Perri F; Della Vittoria Scarpati G; Giuliano M; D'Aniello C; Gnoni A; Cavaliere C; Licchetta A; Pisconti S
    Anticancer Drugs; 2015 Nov; 26(10):1017-25. PubMed ID: 26241803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed-type hypersensitivity (DTH) immune response related with EBV-DNA in nasopharyngeal carcinoma treated with autologous dendritic cell vaccination after radiotherapy.
    Li F; Song D; Lu Y; Zhu H; Chen Z; He X
    J Immunother; 2013 Apr; 36(3):208-14. PubMed ID: 23502768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epstein-Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma.
    Huang J; Fogg M; Wirth LJ; Daley H; Ritz J; Posner MR; Wang FC; Lorch JH
    Cancer; 2017 Jul; 123(14):2642-2650. PubMed ID: 28222215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for nasopharyngeal cancer-a review.
    Jain A; Chia WK; Toh HC
    Chin Clin Oncol; 2016 Apr; 5(2):22. PubMed ID: 27121882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The criteria to confirm the role of Epstein-Barr virus in nasopharyngeal carcinoma initiation.
    Gu AD; Zeng MS; Qian CN
    Int J Mol Sci; 2012 Oct; 13(10):13737-47. PubMed ID: 23202978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for EBV-Associated Nasopharyngeal Carcinoma.
    Hong M; Tang K; Qian J; Deng H; Zeng M; Zheng S; Ding K; Du Y; Sun R
    Crit Rev Oncog; 2018; 23(3-4):219-234. PubMed ID: 30311576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy for Epstein-Barr virus-associated cancers in children.
    Straathof KC; Bollard CM; Rooney CM; Heslop HE
    Oncologist; 2003; 8(1):83-98. PubMed ID: 12604735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.